Semaglutide

BACKGROUND: Pharmacologic therapies for heart failure with preserved ejection fraction (HFpEF) have shown limited efficacy, and the impact of GLP-1 receptor agonists (GLP-1 RAs) remains unclear. This meta-analysis evaluates their effects on mortality…

BackgroundAlzheimer's disease (AD) causes cognitive function disorder and has become the preeminent cause of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists, semaglutide, have shown positive effects on promoting the cognitive function. Ho…

BACKGROUND: This study systematically compares the risk of long-term ocular adverse events between subcutaneous and oral semaglutide preparations to assess pathway-specific safety differences. METHODS: In this study, the Report odds ratio (ROR) techn…

AIMS: Semaglutide, a novel long-acting GLP-1RA, stimulates insulin and suppresses islet-secreted glucagon to reduce glucose levels. It has been unveiled that m6A mRNA modification plays a pivotal role in regulating β cell function. However, it remain…

INTRODUCTION: The mechanistic role of glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists (GLP-1RAs) in modulating brain functional activity has been inadequately examined. Mental disorders are characterized by dysregulated functional connect…

: Semaglutide is a Glucagon-like peptide-1 receptor agonist (GLP-1RA) used in the treatment of type 2 diabetes mellitus (T2DM) and weight management. While its clinical benefits are well established, concerns have emerged over off-label use, underrep…

AIMS: Data support favourable haemodynamic benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on improving cardiac structural abnormalities and function in patients with heart failure (HF). However, the direct haemodynamic effects of G…

BACKGROUND: Here we show results of 1,131 patients on therapy with semaglutide who underwent a comprehensive clinical protocol utilizing the Individualized Virtual Integrative Medicine (IVIM) approach, evaluating the protocol as a comprehensive clini…

Polycystic ovarian syndrome (PCOS) is the most common endocrinopathy in reproductive-aged women worldwide; however, treatment modalities often lack cohesion due to its multifactorial pathophysiology. PCOS is suspected of inducing insulin resistance.…

AIMS: To evaluate the long-term efficacy of a GLP-1 receptor agonist (GLP-1RA, Semaglutide) as an adjunct to insulin therapy in adults with type 1 diabetes (T1D), using continuous glucose monitoring (CGM) metrics alongside weight and metabolic outcom…

BACKGROUND: Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a widely used drug for the treatment of type 2 diabetes that offers significant cardiovascular benefits. RESULTS: This review systematically examines the proteomic and me…

BACKGROUND: GLP-1 receptor agonists (GLP-1 RA) reduce major adverse cardiovascular events in patients with diabetes mellitus and atherosclerotic cardiovascular disease (ASCVD) or increased cardiovascular risk. Recently, the GLP-1 RA semaglutide was r…

INTRODUCTION: Sphingolipid metabolism has been implicated in many diseases including cancer, pathologic inflammation, viral infection, neurologic pathologies and metabolic pathologies, including obesity and diabetes. We have previously shown that opa…

BACKGROUND: No head-to-head comparisons of semaglutide formulations currently exist in the literature. In practice, many may think that oral and injectable semaglutide formulations are interchangeable, although there is currently limited real-world d…

IMPORTANCE: Obesity, a chronic disease with escalating global prevalence, poses considerable health risks. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), including liraglutide, semaglutide, and tirzepatide, have demonstrated efficacy for weigh…

PURPOSE OF REVIEW: The "obesity paradox" describes the counterintuitive observation that overweight and mildly obese individuals with cardiovascular disease (CVD) may have better outcomes than those with normal weight. This paradox is particularly in…